talquetamab
janssen
['monumental-1', 'multiplemyeloma', 'janssen']
for us #hcps attending #ash22, watch dr. ajai chari ( ) present safety &amp; efficacy results from phase 1/2 monumental-1 study investigating gprc5dxcd3 bispecific antibody for treatment of relapsed/refractory #multiplemyeloma. 
Dedicated to sharing Janssen Oncology scientific communications for US HCPs. Account run by Janssen Global Services LLC. Review our Guidelines: https://t.co/uieWByQjn3.